BCS? [Design Issues]

posted by The Outlaw Torn – Europe, 2012-11-29 09:58 (4956 d 09:54 ago) – Posting: # 9630
Views: 12,478

❝ With nothing published this will be a tough job (I wouldn’t even think about it). Even if one overcomes all these obstacles, the risk assessment will be the show-stopper.


Goodmorning Europe and Hello ROW,

Helmut, would you mind expanding a tad on what you mean by the risk assessment being a party pooper? Is it because mebeverine doesn't have much of a history (sparce published literature data, as you mentioned) or any post-marketing data? Are you talking pharmacovigilance here?

Although we haven't personally gone the BCS biowaiver route yet, it would be useful to have a more comprehensive understanding of the process.

Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
169 visitors (0 registered, 169 guests [including 29 identified bots]).
Forum time: 20:53 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5